The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease | Nature https://t.co/61BlMJsPFP

RT @Dra_TeraizaMesa: El anticuerpo #aducanumab reduce las placas A- Beta de la enfermedad de #Alzehimer Bastante prometedor The antibody #…

RT @Dra_TeraizaMesa: El anticuerpo #aducanumab reduce las placas A- Beta de la enfermedad de #Alzehimer Bastante prometedor The antibody #…

El anticuerpo #aducanumab reduce las placas A- Beta de la enfermedad de #Alzehimer Bastante prometedor The antibody #aducanumab reduces Aβ plaques in #Alzheimer’s disease #Neurociencias #Neurosciencie | Nature https://t.co/Y3zbCETnuE

同カフェでの紹介論文。Nature https://t.co/6DCI423NZy

RT @KonttinenHenna: News & views by Eric Reiman: https://t.co/aOgHhuzad5 More skeptical view by Derek Lowe with the slides from Biogen: ht…

RT @bintburton: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. With increasing number of cases of Alzheimer's a timely…

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. With increasing number of cases of Alzheimer's a timely study. https://t.co/4stAlK2274 via @rightrelevance thanks @australisterry

RT @AustralisTerry: Get this on the PBS ⁦@GregHuntMP⁩ The antibody aducanumab reduces Aβ plaques in #Alzheimer's disease. - PubMed - NCBI…

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

RT @AustralisTerry: Get this on the PBS ⁦@GregHuntMP⁩ The antibody aducanumab reduces Aβ plaques in #Alzheimer's disease. - PubMed - NCBI…

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

RT @AustralisTerry: Get this on the PBS ⁦@GregHuntMP⁩ The antibody aducanumab reduces Aβ plaques in #Alzheimer's disease. - PubMed - NCBI…

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

News & views by Eric Reiman: https://t.co/aOgHhuzad5 More skeptical view by Derek Lowe with the slides from Biogen: https://t.co/rNwheRwtEH Original study: https://t.co/zp0gnGSoK4

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

RT @TeeHeemels: Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL vi…

Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL via @statnews Read the original paper by Sevigny et al. Nature, here https://t.co/9OQ77LAuOO News and Views by Eric Reiman, here http

@RebeccaWellsMD @rburstein16 @daviddodick @SHSHeadache @AANMember Um sorry - antibody targeting of brain disorders - for at least two decades https://t.co/BI83PlKHdp and still going strong https://t.co/RvYtgNRGdJ

https://t.co/bsIRKh4FD9 So sad how we live inn a society where we have to drop dead!

Forbes MiaFarrow This is the one that's important! I have followed this drug & know what the experts say. Dale Denney Dr. Sanjay Gupta Sad when society wants people to "Drop Dead". https://t.co/bsIRKh4FD9

@tarahaelle @jamesheathers @chrishendel @AHCJ_Pia @justsaysinmice Now. When someone is trying to calculate translational success rate, this one goes in the red column for team mice. It slowed disease progression and cleared plaques in mice. Super promising

アミロイドβに対する抗体開発↓ https://t.co/SRs331Tb3A でもどれだけ抗体がBBBを通過できるのだろう？ 現在は抗体を脳に届ける研究も進んでいる↓ 『Discovery of novel blood brain barrier targets to enhance brain uptake of therapeutic antibodies（Neuron）』

RT @CambridgeNeuro1: Tragically, less than three years after this exciting Nature paper showing aducanumab reduces Aβ plaques in an Alzheim…

Tragically, less than three years after this exciting Nature paper showing aducanumab reduces Aβ plaques in an Alzheimer’s disease model and in people... the two phase 3 trials are stopped early on the grounds of futility. https://t.co/5icTEwIeLZ

そもそもアルツハイマーなんて薬で治すんじゃなくて自分で社会活動をして脳を活性化させるくらいしか回復方法ないでしょ。 淡い期待

RT @AntHolmes27: Biogen halts Alzheimer's drug trials in major setback for biotech. Another expensive PhIII failure despite promising precl…

これかエーザイのやつ

RT @monopole0001: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/NdFBDEH15j

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/NdFBDEH15j

RT @HattoriM: フェーズ３で治験中止になったエーザイのaducanumabって2016年にNatureの表紙飾ったやつか。。やはり神経変性疾患の治療薬は鬼門やな。。(∩´﹏`∩) https://t.co/nQGM1qyOcS https://t.co/9n0fjX…

Biogen halts Alzheimer's drug trials in major setback for biotech. Another expensive PhIII failure despite promising preclinical data (https://t.co/DBUbDryTD9). Treating AD is complex & we need new preclinical models based on human biology. https://t.c

@BufferSteven @CarBombBoom13 @DarylRhysJones @NHL 1- prodromal or mild AD 2- amyloid PET imaging 3- anti-amyloid antibody Paper: https://t.co/yrrL35a89h

Could this be the return of successful antibody treatment for Alzheimer's? Sevigny et al. at Biogen have shown that aducanumab has the potential to reduce characteristic Aβ plaques commonly associated with Alzheimer's pathology. https://t.co/Z0OJxnpkgb htt

‘The antibody aducanumab reduces Aβ plaques in #Alzheimer's disease.’ a @DovePress article on #ScienceOpen: https://t.co/zBewbSOYvH #WorldAlzheimersDay

@amitvkhera @psychgenomics Aducanumab (antibody against AB) first AD drug to show (highly significant) effect on plaques on PET and had nominal effect on MMSE in phase 2 of prodromal to mild AD (https://t.co/L7OFn0yBEn): results from phase 3 in 2019

The academic journal article that the about article was based on...https://t.co/erNJqgINrp. My cousin Robert Scannevin, is one of the authors!

@jordixiol @Dereklowe @MaverickNY @WilliamGerber1 More info on Aducanumab: https://t.co/XwUXpLNm0q

@Shaleo24 shush, here it is : https://t.co/wSqcgnEm7R THANK YOU LOOOOVE !

With aducanumab in the news, a look back at the paper in Nature: https://t.co/zTCtRES8zq $BIIB https://t.co/ihG2LB9jVy

RT @OrenoSource: 臨床試験薬、アルツハイマー病に「目覚ましい」効果 AFP https://t.co/y67KRfjuVF アミロイドβに対する抗体薬aducanumabの投与によりアミロイド斑が除去されたという臨床試験結果（nature）→ https:/…

RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/FE5w2mtFhx

The amyloid hypothesis: Aβ plaques shrink & cognitive function improves with aducanumab in AD https://t.co/0KdJJztga3

Synaptic dysfunction https://t.co/1yJngfFw7w #HelterSkelterChallenge

Aducanumab the way to go for the treatment of Alzheimer's diseases? #dementia https://t.co/ZSuzvMT3i7

The hype has died down, but I'm hopeful for positive #aducanumab PhIII data in 2020. #Alzheimers https://t.co/OsJlLrJTYW https://t.co/gpTuYnQ1ft

REMARKABLE! Hope it works!!! https://t.co/GSkkohkXJN

Exciting news - potential drug to slow progression of Alzheimer's dementia. https://t.co/ipyn3PNQye

Alzheimer’s disease: deposits of Aβ plaques, neurofibrillary tangles, synaptic dysfunction & neurodegeneration https://t.co/o5YpvP3AYa

Good catch @NathanStall. Table 2 in fact indicates 2 in the placebo group had ARIA (contrary to the text) https://t.co/GlzEjer6sY #GeriMedJC

Fig 2c: change from baseline MMSE in aducanumab-treated patients https://t.co/G1tIldVqVZ #GeriMedJC https://t.co/Rhp5JILn84

Fig 2c: change from baseline CDR-SB in aducanumab-treated patients https://t.co/G1tIled2kz #GeriMedJC https://t.co/gv2FmagJMc

Fig 2a: amyloid plaque reduction, SUVR values https://t.co/G1tIldVqVZ #GeriMedJC https://t.co/DIWB2UzVPG

Table 2: most common adverse effects were amyloid-related imaging abnormalities, headache, UTI, URTI https://t.co/G1tIled2kz #GeriMedJC https://t.co/nnZYxDtEGS

Figure 1: Treatment reduced brain Aβ plaques in a dose- and time-dependent fashion. https://t.co/G1tIled2kz #GeriMedJC https://t.co/n1OVWzbBQj

Clinical assessments were exploratory as the study was not powered to detect clinical change. https://t.co/G1tIldVqVZ #GeriMedJC

Sensitivity analyses done using a mixed model for repeated measures. https://t.co/G1tIldVqVZ #GeriMedJC

Nominal P values presented with no adjustments for multiple comparisons. https://t.co/G1tIldVqVZ #GeriMedJC

Primary analyses based on observed data with no imputation for missing values. Fair? https://t.co/G1tIldVqVZ #GeriMedJC

Table 1. Baseline characteristics. Like your patients? https://t.co/G1tIled2kz #GeriMedJC https://t.co/iYLKpP8Opt

N = 165. Of these patients, 125 completed and 40 discontinued treatment https://t.co/G1tIldVqVZ #GeriMedJC

Intervention: IV aducanumab (1, 3, 6, or 10 mg/kg) or placebo once every 4 weeks for 52 weeks https://t.co/G1tIldVqVZ #GeriMedJC

Inclusion criteria: 50–90 years old and meeting clinical criteria for either prodromal or mild AD https://t.co/G1tIldVqVZ #GeriMedJC

Study design: multicentre, randomized, 12-month, double-blind, placebo-controlled, multiple-dose https://t.co/G1tIled2kz #GeriMedJC

Objective: evaluate safety and tolerability of aducanumab in prodromal AD or mild AD #dementia https://t.co/G1tIled2kz #GeriMedJC

.@NathanStall starts #GeriMedJC discussion with study of interim results of aducanumab trial for Alzheimer's disease https://t.co/XMDZjDE91N

Need links to the article for #GeriMedJC? Starts in 5 mins! https://t.co/XMDZjDE91N https://t.co/LXNufPoBqf

Source: https://t.co/wZBV6W1YkE (h/t >> https://t.co/57zsviQgOu) https://t.co/yDMkbX8ap5

RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…

RT @ibrahimimam2000: Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm

RT @ibrahimimam2000: Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm

Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm

RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…

L'anticós aducanumab redueix les plaques Aβ en la malaltia d'Alzheimer. https://t.co/l2SLw79Bfw https://t.co/SiU3WKr70w

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Jeff Sevigny, Ping Chiao, Thierry Bussière,... https://t.co/bjeufJpiz2

RT @FutureofHealth: #Alzheimer #AlzheimersAwareness antibody aducanumab https://t.co/Nvg3N7S6KG

#Alzheimer #AlzheimersAwareness antibody aducanumab https://t.co/Nvg3N7S6KG

RT @MMUNeuroscience: Hard not to get excited about the latest results using #aducanumab in #Alzheimers patients! Excited for Phase 3. https…

RT @cynthiaermshar: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/by0CdIPjaR #EndAlz #FindACure https://t.…

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/by0CdIPjaR #EndAlz #FindACure https://t.co/FLjSBqYJ1Y

RT @Hesso_F_Sci: aducanumab, which selecively bind aggergated amyloid beta was claimed to work. https://t.co/qNqXWGNPo4 https://t.co/nDmVeB…

aducanumab, which selecively bind aggergated amyloid beta was claimed to work. https://t.co/qNqXWGNPo4 https://t.co/nDmVeB3vql

Aducanumab reduces amyloid Aß- plaques in (early stage) Alzheimer´s Disease according (small) phase 1B- study https://t.co/1cl4Aa8rTA

RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/wvwtvCyqe0

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/Tl4wwUSsP3

Glimmer of hope? https://t.co/Z9j2CJs5Vl

Article 1: aducanumab for Alzheimer's dementia #geriupdate16 @dellightd https://t.co/motuiwGfIX https://t.co/WdD2z9j5a7

Una nueva luz en la batalla frente a la enfermedad de Alzheimer: https://t.co/OwvDTTj1YN.

https://t.co/UwV6NTLioh

EVIDENCE: The antibody Aducanumab reduces amyloid plaques in Alzheimer's Disease. https://t.co/c9K44uVTDO @hthsci4bb3 #hittingtheheadlines

#PSY391 https://t.co/knbLD88FBd

Hope. https://t.co/v1YD0WdWaI

The antibody #Aducanumab reduces Aβ plaques in #Alzheimers; needs confirmation from ongoing phase 3 clinical trial. https://t.co/is66xROPB6

The antibody #aducanumab reduces Aβ plaques in #Alzheimer's disease. https://t.co/4X9lMjnyTB

Resultados del ensayo preclínico fase Ib de aducanumab, vía de investigación esperanzadora contra el #Alzheimer https://t.co/PZ95LdCoK8